Health Insurer Recommends RSV Prevention for Infants - New RSV vaccine guidelines roll out as infections surge in 2024

Respiratory syncytial virus (RSV) infections are on the rise, particularly affecting infants and older adults. Health officials are now urging stronger preventive measures, including vaccination for high-risk groups. New guidelines have been introduced to protect the most vulnerable during peak seasons.

In June 2024, the German Standing Committee on Vaccination (STIKO) recommended nirsevimab as a standard prophylactic treatment for all newborns and infants in their first RSV season. The drug should be given shortly after birth for those born between October and March or between September and November for babies born from April to September. This recommendation remains in place through 2026.

IKK Südwest, a health insurer covering around 600,000 people in Rhineland-Palatinate, Hesse, and Saarland, reported roughly 700 RSV cases among insured infants in 2024. Some of these cases required hospital treatment. While the number of RSV-related hospital stays has decreased compared to previous years, the virus continues to pose a serious risk.

RSV spreads through respiratory droplets, making it highly contagious. Infected individuals are advised to stay away from communal settings until symptoms fade. To further reduce transmission, health authorities also recommend RSV vaccination for everyone aged 75 and older.

The new STIKO guidelines aim to shield infants from severe RSV complications during their first high-risk season. With nirsevimab now standard for newborns and vaccinations encouraged for older adults, health officials hope to curb hospitalisations. Still, RSV remains a persistent threat, requiring ongoing vigilance and preventive action.